Literature DB >> 27230975

Acute hemolysis in a patient with a newly diagnosed glioblastoma.

Adrian G Murphy1, Stuart A Grossman1.   

Abstract

We describe a 62-year-old of Egyptian origin who presented with sudden, severe and symptomatic anemia requiring hospitalization shortly after beginning concurrent radiation and temozolomide for his newly diagnosed glioblastoma. He had also recently been started on steroids, anticonvulsants and Pneumocystis jirovecii prophylaxis. He was ultimately diagnosed with G6PD deficiency with an acute hemolytic anemia precipitated by dapsone. Screening for G6PD deficiency should be considered in high-risk patient populations where P. jirovecii prophylaxis is planned.

Entities:  

Keywords:  dapsone; glioblastoma multiforme; glucose-6-phosphate dehydrogenase deficiency (G6PD); hemolytic anemia

Mesh:

Substances:

Year:  2016        PMID: 27230975      PMCID: PMC6042633          DOI: 10.2217/cns-2015-0009

Source DB:  PubMed          Journal:  CNS Oncol        ISSN: 2045-0907


  25 in total

1.  Methemoglobinemia and hemolysis in a patient with G6PD deficiency treated with rasburicase.

Authors:  Mohamad Bassam Sonbol; Hemang Yadav; Rakhee Vaidya; Vishal Rana; Thomas E Witzig
Journal:  Am J Hematol       Date:  2012-05-10       Impact factor: 10.047

2.  Prevalence of glucose-6-phosphate dehydrogenase deficiency in U.S. Army personnel.

Authors:  Troy D Chinevere; Clinton K Murray; Earl Grant; Gregory A Johnson; Felix Duelm; Duane R Hospenthal
Journal:  Mil Med       Date:  2006-09       Impact factor: 1.437

3.  Toxicity and efficacy of daily dapsone as Pneumocystis jiroveci prophylaxis after hematopoietic stem cell transplantation: a case-control study.

Authors:  Dario Sangiolo; Barry Storer; Richard Nash; Lawrence Corey; Chris Davis; Mary Flowers; Robert C Hackman; Michael Boeckh
Journal:  Biol Blood Marrow Transplant       Date:  2005-07       Impact factor: 5.742

4.  Aerosolized pentamidine prophylaxis for Pneumocystis carinii pneumonia after allogeneic marrow transplantation.

Authors:  T K Marras; K Sanders; J H Lipton; H A Messner; J Conly; C K Chan
Journal:  Transpl Infect Dis       Date:  2002-06       Impact factor: 2.228

Review 5.  Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials.

Authors:  Hefziba Green; Mical Paul; Liat Vidal; Leonard Leibovici
Journal:  Mayo Clin Proc       Date:  2007-09       Impact factor: 7.616

Review 6.  G6PD deficiency: the genotype-phenotype association.

Authors:  Philip J Mason; José M Bautista; Florinda Gilsanz
Journal:  Blood Rev       Date:  2007-07-03       Impact factor: 8.250

7.  The etiology of treatment-related lymphopenia in patients with malignant gliomas: modeling radiation dose to circulating lymphocytes explains clinical observations and suggests methods of modifying the impact of radiation on immune cells.

Authors:  Susannah Yovino; Lawrence Kleinberg; Stuart A Grossman; Manisha Narayanan; Eric Ford
Journal:  Cancer Invest       Date:  2013-02       Impact factor: 2.176

Review 8.  Use of dapsone in the prevention and treatment of Pneumocystis carinii pneumonia: a review.

Authors:  W T Hughes
Journal:  Clin Infect Dis       Date:  1998-07       Impact factor: 9.079

9.  Noninferiority of glucose-6-phosphate dehydrogenase deficiency diagnosis by a point-of-care rapid test vs the laboratory fluorescent spot test demonstrated by copper inhibition in normal human red blood cells.

Authors:  J Kevin Baird; Mewahyu Dewi; Decy Subekti; Iqbal Elyazar; Ari W Satyagraha
Journal:  Transl Res       Date:  2014-09-28       Impact factor: 7.012

10.  Pneumocystis carinii pneumonia in HIV negative patients with primary brain tumors.

Authors:  Anuj K Mahindra; Stuart A Grossman
Journal:  J Neurooncol       Date:  2003-07       Impact factor: 4.506

View more
  4 in total

1.  Hemolytic anemia associated with dapsone PCP prophylaxis in GBM patients with normal G6PD activity.

Authors:  Lisa R Rogers; Peter Oppelt; Lalitha Nayak
Journal:  Neuro Oncol       Date:  2020-06-09       Impact factor: 12.300

2.  Hematological adverse events in the management of glioblastoma.

Authors:  Catherine R Garcia; Zin W Myint; Rani Jayswal; Chi Wang; Rachael M Morgan; Allison R Butts; Heidi L Weiss; John L Villano
Journal:  J Neurooncol       Date:  2021-11-24       Impact factor: 4.130

Review 3.  G6PD Variants and Haemolytic Sensitivity to Primaquine and Other Drugs.

Authors:  Germana Bancone; Cindy S Chu
Journal:  Front Pharmacol       Date:  2021-03-15       Impact factor: 5.810

4.  Pneumocystis jirovecii prophylaxis in patients treated for high-grade gliomas: a survey among neuro-oncologists.

Authors:  Nebojša Skorupan; Surabhi Ranjan; Seema Mehta; Olga Yankulina; Nathan Nenortas; Stuart Grossman; Xiaobu Ye; Matthias Holdhoff
Journal:  Neurooncol Pract       Date:  2018-11-29
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.